Ergoteles’s AtriCure ATRC Stock Holding History

Ergoteles’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,055	Closed	-$1.1M	–	1440
2022 Q3	$1.1M	Buy	28,055 +21,391	+321%	+$979K	0.04%	443
2022 Q2	$272K	Buy	6,664 +2,264	+51%	+$107K	0.01%	1157
2022 Q1	$289K	Sell	4,400 -1,891	-30%	-$123K	0.01%	852
2021 Q4	$437K	Buy	+6,291	New	+$457K	0.02%	693

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ergoteles's ATRC Position: Q4 2022 in Review

Ergoteles sold out of AtriCure (ATRC) in Q4 2022, closing a stake of 28,055 shares — an estimated $1.1M sold.

Ergoteles first reported a position in ATRC in Q4 2021 and held it in 4 quarters. The position peaked at $1.1M in Q3 2022. 211 funds tracked by Wall St. Rank hold ATRC as of Q4 2022.

Ergoteles reported no remaining AtriCure position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 28,055 AtriCure shares in Q4 2022, an estimated $1.1M.
Ergoteles first reported a position in AtriCure in Q4 2021 and held it in 4 quarters.
Ergoteles's AtriCure position peaked at $1.1M in Q3 2022.
211 funds tracked by Wall St. Rank held AtriCure as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.